XTANT MEDICAL HOLDINGS, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 10 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-08-15: Reporting owner Schallenberger Mark A.; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-08-15: Reporting owner Neils Scott C; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-08-15: Reporting owner Browne Sean E; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-08-15: Reporting owner Brandt Kevin D; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
XTNT insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-08-15 | Schallenberger Mark A. Officer (Chief Operations Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,501 135,501 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | Neils Scott C Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +135,501 135,501 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | Browne Sean E Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +203,252 203,252 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | Brandt Kevin D Officer (Chief Commercial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +140,583 140,583 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | Vizirgianakis Stavros G. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +42,345 42,345 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | MITCHELL-KELLER LORI D Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,230 28,230 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | McNamara Robert Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,230 28,230 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | Beeson Jonn R. Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,230 28,230 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-08-15 | BAKEWELL JOHN K Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,230 28,230 owned after | $1.20 exercise price | $1.18 | 2023-08-17 |
| 2023-02-15 | Schallenberger Mark A. Officer (Chief Operations Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,000 105,000 owned after | $0.77 exercise price | $0.73 | 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| NEPHROS INC (NEPH) | United States | $0.046B | 23.02 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |